Loading clinical trials...
Loading clinical trials...
Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50. Vasculitis lesions cause thickening of the arterial wall, visible on temporal artery biopsy (TAB) or vascular imaging (echo-Doppler, angio-CT, angio-MRI, 18FDG PET-CT). This is a severe disease that can lead to blindness. Early diagnosis is essential, so that steroids therapy can be started as soon as possible to prevent complications. Doppler ultrasonography of the temporal arteries provides rapid, non-invasive diagnostic support. However, the recommendations do not specify how soon temporal artery Doppler should be performed after steroids treatment, except that the halo sign would disappear after about 5 days on steroids. Sensitivity seems to be better when the examination is performed early, but the time taken for the halo sign to disappear is unknown. The investigator suggests that the disappearance of the temporal artery halo sign in GCA patients is observed earlier than D14 of steroids treatment usually reported in the literature. He speculates that the sensitivity of the temporal artery Doppler decreases as early as D3 of steroids treatment, and that beyond D7 it is not useful to perform this examination as its sensitivity becomes too low.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Centre Hospitalier du Mans
Le Mans, Sarthe, France
CHU d'Angers
Angers, France
CHU Caen Normandie
Caen, France
CHU Dijon - Hôpital François Mitterrand
Dijon, France
Groupe hospitalier La Rochelle-Ré-Aunis
La Rochelle, France
CHU Nantes
Nantes, France
Start Date
September 1, 2025
Primary Completion Date
October 1, 2027
Completion Date
October 1, 2027
Last Updated
July 11, 2025
64
ESTIMATED participants
Doppler Ultrasound
PROCEDURE
Lead Sponsor
Centre Hospitalier le Mans
NCT07465523
NCT06887062
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions